This sounds interesting:
insidenova.com/news/state/t...
"A hallmark of Parkinson's disease is the abnormal accumulation of a protein called alpha-synuclein, which leads to unhealthy brain cells and neurodegeneration. Promising treatments to reduce alpha-synuclein accumulation, however, have been limited by their inability to cross the blood-brain barrier (BBB) and reach the target.
"José Obeso, MD, PhD, of the Centro Integral de Neurociencias (HM CINAC) in Madrid recently led the first clinical trial in the world to use focused ultrasound to temporarily and reversibly open the BBB in the putamen region of the striatum of Parkinson's patients. To date, seven patients have been treated.
"In another groundbreaking clinical trial, Nir Lipsman, MD, PhD, is co-leading a team of researchers at Sunnybrook Health Sciences Centre and University Health Network in Toronto who are the first in the world to use focused ultrasound.
"The goal of this trial is to examine the safety of temporarily opening the blood-brain barrier in key motor regions known to be implicated in Parkinson's disease and delivering promising therapeutics directly to these areas of the brain," said Dr. Lipsman, Director of Sunnybrook's Harquail Centre for Neuromodulation.